Extensive CArdioVAscular Characterization and Follow-Up of Patients Receiving Immune Checkpoint Inhibitors: A Prospective Multicenter Study

• Egile Nagusiak: Danielle Delombaerde (Egilea), Johan De Sutter (Egilea), Lieselot Croes (Egilea), Delphine Vervloet (Egilea), Veronique Moerman (Egilea), Nico Van de Veire (Egilea), Anne-Marie Willems (Egilea), Kristien Wouters (Egilea), Marc Peeters (Egilea), Hans Prenen (Egilea), Christof Vulsteke (Egilea)
• Formatua: Liburua
• Argitaratua: MDPI AG, 2023-04-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Background: The increasing use of immune checkpoint inhibitors (ICIs) in the treatment of both advanced and early stages of various malignancies has resulted in a substantial increase in the incidence of cardiovascular (CV) immune-related adverse events (irAEs). The current follow-up guidelines are...